Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556580 | 0.89 | SIGMAR1 (0.41) | ALDH1A1HRH3CNR1SIGMAR1CYP2D6 | |
| SCHEMBL17797162 | 0.89 | SIGMAR1 (0.41) | ALDH1A1HRH3CNR1SIGMAR1CYP2D6 | |
| SCHEMBL1252458 | 0.80 | MC4R (0.46) | ALDH1A1CNR1KDM4E | |
| SCHEMBL30577958 | 0.80 | MC4R (0.46) | ALDH1A1CNR1KDM4E | |
| SCHEMBL17805278 | 0.80 | MC4R (0.46) | ALDH1A1CNR1KDM4E | |
| SCHEMBL17805293 | 0.80 | BCHE (0.47) | ALDH1A1HRH3KDM4EDRD3 | |
| SCHEMBL19600503 | 0.80 | HDAC6 (0.35) | CNR1CYP2D6 | |
| SCHEMBL26821992 | 0.79 | CXCR4 (0.51) | ALDH1A1CNR1 | |
| SCHEMBL23616077 | 0.77 | MC4R (0.41) | CNR1KDM4E | |
| SCHEMBL19600507 | 0.76 | BCHE (0.44) | ALDH1A1MEN1KMT2AHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326261-A1 | BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF | AP2A2, ATP2A2, SLC20A2 | ALDH1A1 501/4885MEN1 2494/4885RAD52 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.